Vor Biopharma Inc. Operating Lease Cost
Vor Biopharma Inc. (VOR) reported Operating Lease Cost of $158.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-11
- Vor Biopharma Inc. operating lease, cost for the quarter ending 2026-06-30 was $158.00K, a 98.79% decline year-over-year.
- Vor Biopharma Inc. operating lease, cost for the quarter ending 2026-03-31 was $158.00K, a 91.90% decline year-over-year.
- Vor Biopharma Inc. operating lease, cost for the quarter ending 2025-12-31 was $159.00K, a 91.85% decline year-over-year.
- Vor Biopharma Inc. operating lease, cost for the quarter ending 2025-09-30 was $83.00K, a 95.75% decline year-over-year.
- Vor Biopharma Inc. operating lease, cost for fiscal 2025 was $15.28M, a 95.77% increase from fiscal 2024.
- Vor Biopharma Inc. operating lease, cost for fiscal 2024 was $7.80M, a 0.03% increase from fiscal 2023.
- Vor Biopharma Inc. operating lease, cost for fiscal 2023 was $7.80M, a 21.24% increase from fiscal 2022.
- Vor Biopharma Inc. operating lease, cost for fiscal 2022 was $6.43M, a 113.29% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $158.00K 10-Q · filed 2026-08-11 | $316.00K 10-Q · filed 2026-08-11 | $475.00K derived: sum of 3 quarters · filed 2026-08-11 | $558.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $158.00K 10-Q · filed 2026-05-13 | $317.00K derived: sum of 2 quarters · filed 2026-05-13 | $400.00K derived: sum of 3 quarters · filed 2026-05-13 | $13.48M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $159.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $242.00K derived: sum of 2 quarters · filed 2026-03-30 | $13.33M derived: sum of 3 quarters · filed 2026-08-11 | $15.28M 10-K · filed 2026-03-30 |
| 2025-09-30 | $83.00K 10-Q · filed 2025-11-13 | $13.17M derived: sum of 2 quarters · filed 2026-08-11 | $15.12M 10-Q · filed 2025-11-13 | $17.07M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $13.09M 10-Q · filed 2026-08-11 | $15.04M 10-Q · filed 2026-08-11 | $16.99M derived: sum of 3 quarters · filed 2026-08-11 | $18.94M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $1.95M 10-Q · filed 2026-05-13 | $3.90M derived: sum of 2 quarters · filed 2026-05-13 | $5.85M derived: sum of 3 quarters · filed 2026-05-13 | $7.80M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $1.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $3.90M derived: sum of 2 quarters · filed 2026-03-30 | $5.85M derived: sum of 3 quarters · filed 2026-03-30 | $7.80M 10-K · filed 2026-03-30 |
| 2024-09-30 | $1.95M 10-Q · filed 2025-11-13 | $3.90M derived: sum of 2 quarters · filed 2025-11-13 | $5.85M 10-Q · filed 2025-11-13 | $7.80M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $1.95M 10-Q · filed 2025-08-12 | $3.90M 10-Q · filed 2025-08-12 | $5.85M derived: sum of 3 quarters · filed 2025-08-12 | $7.80M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $1.95M 10-Q · filed 2025-05-14 | $3.90M derived: sum of 2 quarters · filed 2025-05-14 | $5.85M derived: sum of 3 quarters · filed 2025-05-14 | $7.80M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $1.95M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $3.90M derived: sum of 2 quarters · filed 2025-03-20 | $5.85M derived: sum of 3 quarters · filed 2025-03-20 | $7.80M 10-K · filed 2025-03-20 |
| 2023-09-30 | $1.95M 10-Q · filed 2024-11-07 | $3.90M derived: sum of 2 quarters · filed 2024-11-07 | $5.85M 10-Q · filed 2024-11-07 | $7.78M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $1.95M 10-Q · filed 2024-08-08 | $3.90M 10-Q · filed 2024-08-08 | $5.83M derived: sum of 3 quarters · filed 2024-08-08 | $7.82M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $1.95M 10-Q · filed 2024-05-09 | $3.88M derived: sum of 2 quarters · filed 2024-05-09 | $5.88M derived: sum of 3 quarters · filed 2024-05-09 | $7.47M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $1.93M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | $3.92M derived: sum of 2 quarters · filed 2024-03-20 | $5.51M derived: sum of 3 quarters · filed 2024-03-20 | $6.43M 10-K · filed 2024-03-20 |
| 2022-09-30 | $1.99M 10-Q · filed 2023-11-07 | $3.59M derived: sum of 2 quarters · filed 2023-11-07 | $4.51M 10-Q · filed 2023-11-07 | $5.26M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $1.59M 10-Q · filed 2023-08-10 | $2.51M 10-Q · filed 2023-08-10 | $3.27M derived: sum of 3 quarters · filed 2023-08-10 | $4.03M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $920.00K 10-Q · filed 2023-05-11 | $1.68M derived: sum of 2 quarters · filed 2023-05-11 | $2.43M derived: sum of 3 quarters · filed 2023-05-11 | $3.19M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $757.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $1.51M derived: sum of 2 quarters · filed 2023-03-23 | $2.27M derived: sum of 3 quarters · filed 2023-03-23 | $3.02M 10-K · filed 2023-03-23 |
| 2021-09-30 | $756.00K 10-Q · filed 2022-11-10 | $1.51M derived: sum of 2 quarters · filed 2022-11-10 | $2.26M 10-Q · filed 2022-11-10 | $3.01M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $757.00K 10-Q · filed 2022-08-11 | $1.50M 10-Q · filed 2022-08-11 | $2.25M derived: sum of 3 quarters · filed 2022-08-11 | $3.00M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $747.00K 10-Q · filed 2022-05-12 | $1.49M derived: sum of 2 quarters · filed 2022-05-12 | $2.24M derived: sum of 3 quarters · filed 2022-05-12 | $2.53M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $747.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $1.50M derived: sum of 2 quarters · filed 2022-03-14 | $1.78M derived: sum of 3 quarters · filed 2022-03-14 | $1.78M 10-K · filed 2022-03-14 |
| 2020-09-30 | $748.00K 10-Q · filed 2021-11-10 | $1.03M derived: sum of 2 quarters · filed 2021-11-10 | $1.03M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $285.00K 10-Q · filed 2021-08-09 | $285.00K 10-Q · filed 2021-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |